Peptides
Evidence: animal_plus_anecdotal
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Standard: Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Maintenance: Research indicates 200 mcg daily or every other day for maintenance.
Administration: subcutaneousoraltopical
Timing: Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
Duration: 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
KPV is gaining significant attention for gut inflammation, particularly IBD and colitis. Its mechanism is unique among peptides in that it does not require melanocortin receptor binding — instead it uses the PepT1 intestinal peptide transporter for direct intracellular delivery. This makes oral KPV particularly effective for GI-targeted applications. Community reports suggest notable improvement in inflammatory bowel conditions.
Compounding pharmacy or research-grade supplier with COA. Oral formulations require enteric coating or acid-stable preparation.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →